Annual Drug Patent Expirations for LENVIMA
Lenvima is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for LENVIMA.
This drug has one hundred and thirty-two patent family members in thirty-six countries.
The generic ingredient in LENVIMA is lenvatinib mesylate. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
